Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma

Sponsor
First Affiliated Hospital of Kunming Medical University
Study ID
NCT02704767
Phase
PHASE2
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
  • Tarceva — DRUG
  • Placebo — DRUG

Study Details

Tarceva now was established first-line therapy for advanced lung adenocarcinoma with mutant EGFR patients.However,the benefit lasted for about 6-8 months.So we consider to add apatinib,a tyrosine kinase inhibitor of VEGF,to the therapy of these patients.

Key Dates

Start date
Jun 30, 2016
Status verified
Mar 2016
Primary completion
Jun 30, 2019
Completion
Dec 31, 2019

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: TarceP
    Tarceva with Placebo
  • Experimental: TarceA
    Tarceva with Apatinib

Primary Outcome Measure

Progression free survival [ Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months ]

Related Studies